Last reviewed · How we verify

NCT04945928

Safety and Feasibility of Surgery After Conversion Therapy for Locally Advanced and Advanced NSCLC

Active, enrolled NA Last updated 24 May 2024
What this trial tests

NA trial testing Surgery in Pulmonary Neoplasm in 30 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
27 August 2021
Primary endpoint
5 June 2024
5 June 2026

Quick facts

Lead sponsorRuijin Hospital
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment30
Start date27 August 2021
Primary completion5 June 2024
Estimated completion5 June 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Ruijin Hospital

Who can join

18 and older, any sex, with Pulmonary Neoplasm or Advanced Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Lung cancer is one of the most common malignant tumors worldwide and the mortality ranks first in the world. In recent years, with the development of targeted therapy and immunotherapy, the overall survival of lung cancer patients has improved significantly. However, the inoperable advanced tumor remains the main reason for the poor prognosis of lung cancer. Thus, we aim to carry out this single-arm, prospective study to evaluate the safety and feasibility of surgery after conversion therapy for locally advanced and advanced non-small cell lung cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Immunotherapy during the Immediate Perioperative Period: A Promising Approach against Metastatic Disease.
    Sandbank E, Eckerling A, Margalit A, Sorski L, et al · · 2023 · cited 10× · PMID 37623021 · DOI 10.3390/curroncol30080540
  2. Conversion Surgery After Induction Therapy for Initially Unresectable Stage III Non-small Cell Lung Cancer: A Proof-of-Concept Trial.
    Yan Y, Han Y, Niu Z, Zhang X, et al · · 2026 · PMID 41880079 · DOI 10.1245/s10434-026-19461-z

Verify or expand the search:

Other trials of Surgery

Trials testing the same drug.

Other recruiting trials for Pulmonary Neoplasm

Currently open trials in the same condition.

Other Ruijin Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04945928.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing